• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Trending
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • CRO Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Gilead Sciences

Person throwing piece of paper into full waste bin
Biotech

Gilead culls last MASH program, 2 cancer assets

The dropped oncology assets are a DGKα inhibitor and an MCL1 inhibitor, which join a Novo-partnered MASH program in the scrap heap.
Darren Incorvaia Aug 8, 2025 11:50am
Return To Sender stamp on an envelope

Gilead hands back one Arcus cancer candidate from $725M deal

Aug 7, 2025 6:35am
Uninhabited island full of trees

Galapagos builds island of cell therapies amid pipeline pruning

Jul 24, 2025 10:59am
Realistic white price tags collection Special offer or shopping discount label

China biotechs ‘reshaping’ US biopharma: Jefferies report

Jul 14, 2025 2:30pm
Whale swimming in ocean seen from above

Merck wades deeper into HIV PrEP waters with pair of trials

Jul 14, 2025 1:12pm
Gilead

Gilead blames low infection rates for ending 2 RSV trials

Jun 27, 2025 4:09am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2025 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings